Making Better CARs for Kids.
Researchers have found that prior chemotherapy may impair the ability to manufacture effective chimeric antigen receptor (CAR) T-cell therapies. In addition, they determined that T cells that use fatty-acid pathways for fuel had greater potential as CAR T-cell therapies than cells that relied on glycolysis. Their conclusions have led to a change in the timing of T-cell collection.